Ya-Yao HUANG

Ya-Yao Huang

Taiwan

Co-Founder and CEO

Primo Biotechnology Co., Ltd.

I have been worked in radiopharmaceutical field for more than 20 years and worked in Taiwan’s top medical center, National Taiwan University Hospital, for 10 years, where was responsible for R&D and GMP-compliant production of PET radiopharmaceuticals for clinical and preclinical use. During 20 years working in academic institutions, I devote to innovative radiopharmaceutical researches for the benefit of all patients, as well as the method development and process improvement of the automated production of radiopharmaceuticals with high quality. In 2021, I founded Primo Biotechnology with my team in order to promote radiopharmaceuticals in Taiwan and Asia in an effective and sustainable way. Moreover, I am delegated as Taiwan ambassador for the non-profit global organization, Oncidium Foundation since 2021 and hope to promote, support and accelerate the development of radiotheranostics for cancer care, worldwide. Now, we are facing similar challenges in precision healthcare even we are in different countries. However, with more and more awareness for radiopharmaceutical effectiveness in clinic, sincerely hope we could have brainstormed to find out the way to tackle these obstacles and let’s work together to achieve a better global healthcare with the advanced and novel radiopharmaceuticals.

 Radiopharmaceutical development  PET Imaging

 Ph.D, Department of Biomedical Engineering and Environmental Sciences , National Tsing Hua University, R.O.C.  Master, Department of Chemistry, National Sun Yat-Sen University, R.O.C.  Bachelor, Department of Chemical Engineering, I-Shou University, R.O.C.

 Poster Presentation of Basic Science 1st Award, 2020 TSNM Annual Meeting,, Nov. 21, 2020, Tainan, Taiwan  Poster Presentation of Clinical Science (non-physician) 3rd Award, 2 018 TSNM Meeting & 1st EANMA Congress (EANMA2018), Nov. 17-19, 2018, Taipei, Taiwan.  International Abstracts Award Winner of Taiwan, 2017 SNMMI Annual Meeting, USA.

 Wang, Y.F., Lo, C.Y., Chen, L.Y., Chang, C.W., Huang, Y.T., Huang, Y.Y.*, Huang, Y.H.*, Comparing the Detection Performance Between Multiparametric Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen PET/CT in Patients With Localized Prostate Cancer: A Systematic Review and Meta-analysis, Clin Nucl Med . 2023 Jul 1;48(7):e321-e331. (SCI)  Huang, Y.T., Tseng, N.C., Chen, Y.K., Huang, K.H., Lin, H.Y., Huang, Y.Y.*, Hwang, T.I.S,*, Ou, Y.C.*,(2022) The detection performance of F-18-PSMA-1007-PET/CT in primary prostate cancer: A systemic review and meta-analysis., Clin Nucl Med. 1;47(9):755-762 (SCI)  Huang, Y.Y., (2021) Are Asian Countries Ready for Novel Radiopharmaceuticals? Newsletter Oncidium November 2021.  Cheng, M.F., Huang, Y.Y. , Ho, B.Y., Kuo, TC., Hsin, L.W., Shiue, C.Y., Kuo, H.C., Jeng, Y.M., Yen , R.F., Tien, Y.W., (2019) Prospective comparison of (4S)-4-(3-18F-fluoropropyl)-L-glutamate versus 18F-fluorodeoxyglucose PET/CT for detecting metastases from pancreatic ductal adenocarcinoma: a proof-of-concept study. Eur J Nucl Med Mol Imaging 46, 810–820. (SCI)  Chiu, C.H., Huang, Y.Y. *, Tsai, C.L., Chou, T.K., Lo, C.H., Tsai, K.L., Chen, J.G., Chan, S.C., Chiu, C.H., Yen, R.F., (2020) Experience of [18F]FDG Production with Cassette-Type Modules in Four Hospitals of Taiwan, J Radioanal Nucl Chem, 326, 25-32. (SCI)